Literature DB >> 6547067

Cardioprotective actions of pentoxifylline in an animal model of acute myocardial ischaemia.

W Gallenkämper, W Rücker, K Schrör.   

Abstract

The action of pentoxifylline on some of the consequences of acute myocardial ischaemia was studied in cats in vivo. Occlusion of the left anterior descending coronary artery (LAD) for 5 h resulted in a significant elevation in the ST-segment of the ECG, a reduction in free platelet count in right atrial blood and a loss of creatine phosphokinase (CK) and cathepsin D activities in homogenates of the severely ischaemic myocardium as compared to non-ischaemic myocardium. Intravenous infusions of pentoxifylline (0.30 mg kg-1 min-1 for 1 h and 0.15 mg kg-1 min-1 for the remainder of the 5 h observation period, starting 0.5 h after LAD occlusion) significantly reduced the loss of enzymes from the ischaemic myocardium, prevented any further increase in the ST-segment and restored the platelet count to its control level. There were no significant changes in plasma immunoreactive 6-oxo-prostaglandin F1 alpha (6-oxo-PGF1 alpha) and thromboxane B2 (TXB2), although a tendency for a reduction in TXB2 levels was observed. Pentoxifylline seems to affect, beneficially, the myocardium in this animal model of acute myocardial ischaemia. The reason for this cardioprotective action remains to be elucidated. It is, however, noteworthy that the overall profile of action of pentoxifylline resembles that of PGI2 administration in this model.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6547067      PMCID: PMC1986909          DOI: 10.1111/j.1476-5381.1984.tb16121.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Effects of pentoxifylline on red blood cell deformability and blood viscosity under hyperosmolar conditions.

Authors:  H Leonhardt; H G Grigoleit
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-09       Impact factor: 3.000

2.  Platelet aggregation in partially obstructed vessels and its elimination with aspirin.

Authors:  J D Folts; E B Crowell; G G Rowe
Journal:  Circulation       Date:  1976-09       Impact factor: 29.690

3.  Effect of phosphodiesterase inhibitors on heart contractile behaviour, protein kinase activity and cyclic nucleotide levels.

Authors:  M I Argel; L Vittone; A O Grassi; L E Chiappe; G E Chiappe; H E Cingolani
Journal:  J Mol Cell Cardiol       Date:  1980-10       Impact factor: 5.000

4.  Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias.

Authors:  S J Coker; J R Parratt; I M Ledingham; I J Zeitlin
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

5.  Prevention of infarction-induced decrease in circulating platelet count by prostacyclin.

Authors:  R Ohlendorf; E Perzborn; K Schrör
Journal:  Thromb Res       Date:  1980 Aug 15-Sep 1       Impact factor: 3.944

6.  A critical look at currently used indirect indices of myocardial oxygen consumption.

Authors:  D Baller; H J Bretschneider; G Hellige
Journal:  Basic Res Cardiol       Date:  1981 Mar-Apr       Impact factor: 17.165

7.  Preservation of ischemic myocardium by pinane thromboxane A2.

Authors:  K Schrör; E F Smith; M Bickerton; J B Smith; K C Nicolaou; R Magolda; A M Lefer
Journal:  Am J Physiol       Date:  1980-01

8.  The effect of prostacyclin (PGT2) on platelet behaviour. Thrombus formation in vivo and bleeding time.

Authors:  F B Ubatuba; S Moncada; J R Vane
Journal:  Thromb Haemost       Date:  1979-04-23       Impact factor: 5.249

9.  Studies on the protective effect of prostacyclin in acute myocardial ischemia.

Authors:  M L Ogletree; A M Lefer; J B Smith; K C Nicolaou
Journal:  Eur J Pharmacol       Date:  1979-06       Impact factor: 4.432

10.  Prostacyclin prevents ischemia-induced increase of lactate and cyclic AMP in ischemic myocardium.

Authors:  R Rösen; P Rösen; R Ohlendorf; K Schrör
Journal:  Eur J Pharmacol       Date:  1981-02-19       Impact factor: 4.432

View more
  3 in total

1.  Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177).

Authors:  K Schrör; C Thiemermann
Journal:  Br J Pharmacol       Date:  1986-04       Impact factor: 8.739

2.  Pentoxifylline does not reduce infarct size in a canine model of acute myocardial infarction.

Authors:  C A Campbell; C F Clavenna; J Wynne; R A Kloner
Journal:  Br J Pharmacol       Date:  1988-03       Impact factor: 8.739

Review 3.  Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.

Authors:  A Ward; S P Clissold
Journal:  Drugs       Date:  1987-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.